cancer drugs

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

Unsatisfied by how treatments for childhood leukemia failed to prevent the disease’s return, Pinkel combined them all—and virtually cured the disease.

A study uncovers a novel connection between the biomolecule and cancer progression.

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

Mintz’s experiments over her six-decade career were foundational to cancer and genetics research.

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

New experiments suggest the famous tumor-suppressing protein uses viral elements lingering in the genome to get cancerous cells to announce their presence to the immune system.

Researchers turned white blood cells called neutrophils into drug-smuggling “neutrobots,” which penetrated the blood-brain barrier to treat brain cancer in mice.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The oncologist developed lifesaving childhood leukemia treatments and revolutionized chemotherapy.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

Strategies to trick, manipulate, and direct the evolution of tumors

The Vanderbilt University professor was awarded a Nobel Prize for his discovery of epidermal growth factor.

Colorectal tumor cells limit their DNA repair in response to a targeted therapy, giving them a greater chance to develop resistance to the drug.

A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.

The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.